MFAM
BMRN icon

Motley Fool Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Motley Fool Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Sell
3,797
-155
-4% -$8.49K 0.01% 246
2026
Q1 		$223K Buy
3,952
+565
+17% +$32.9K 0.01% 232
2025
Q4 		$201K Sell
3,387
-28,632
-89% -$1.56M 0.01% 238
2025
Q3 		$1.73M Sell
32,019
-33,016
-51% -$1.89M 0.07% 159
2025
Q2 		$3.57M Buy
65,035
+51,682
+387% +$3.04M 0.16% 111
2025
Q1 		$944K Buy
13,353
+41
+0.3% +$2.76K 0.05% 161
2024
Q4 		$875K Sell
13,312
-135,486
-91% -$9.08M 0.05% 160
2024
Q3 		$10.4M Sell
148,798
-1,941
-1% -$162K 0.62% 41
2024
Q2 		$12.4M Buy
150,739
+103,824
+221% +$8.64M 0.82% 29
2024
Q1 		$4.1M Buy
46,915
+2,792
+6% +$250K 0.27% 81
2023
Q4 		$4.25M Sell
44,123
-1,238
-3% -$110K 0.32% 74
2023
Q3 		$4.01M Buy
45,361
+41,929
+1,222% +$3.73M 0.32% 70
2023
Q2 		$297K Buy
+3,432
New +$323K 0.03% 188
2023
Q1 		– Sell
-3,369
Closed -$349K – 122
2022
Q4 		$349K Sell
3,369
-271
-7% -$25.4K 0.04% 178
2022
Q3 		$309K Sell
3,640
-84
-2% -$7.48K 0.03% 187
2022
Q2 		$322K Buy
3,724
+13
+0.4% +$1.03K 0.03% 189
2022
Q1 		$286K Buy
3,711
+3,625
+4,215% +$303K 0.02% 198
2021
Q4 		$8K Buy
+86
New +$7.1K ﹤0.01% 195
2020
Q3 		– Sell
-3,172
Closed -$391K – 165
2020
Q2 		$391K Buy
3,172
+120
+4% +$11.9K 0.04% 154
2020
Q1 		$258K Buy
+3,052
New +$263K 0.03% 158
2019
Q2 		– Sell
-2,827
Closed -$251K – 170
2019
Q1 		$251K Buy
+2,827
New +$262K 0.03% 160
2018
Q4 		– Sell
-2,233
Closed -$217K – 161
2018
Q3 		$217K Buy
+2,233
New +$223K 0.03% 146

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Motley Fool Asset Management's BMRN Position: Q2 2026 in Review

Motley Fool Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 3.9% in Q2 2026, selling an estimated $8.49K and leaving 3,797 shares worth $217K. The position accounts for 0.01% of the portfolio, ranked #246.

Motley Fool Asset Management first reported a position in BMRN in Q3 2018 and has held it in 22 quarters since. The position peaked at $12.4M in Q2 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Motley Fool Asset Management held 3,797 shares of BioMarin Pharmaceuticals worth $217K as of Q2 2026.
  • Motley Fool Asset Management sold 155 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $8.49K.
  • BioMarin Pharmaceuticals made up 0.01% of Motley Fool Asset Management's portfolio in Q2 2026, its #246 holding.
  • Motley Fool Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2018 and has held it in 22 quarters since.
  • Motley Fool Asset Management's BioMarin Pharmaceuticals position peaked at $12.4M in Q2 2024.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Motley Fool Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.